

**EU/RE DIRECTIVE DECLARATION OF CONFORMITY**

This is a declaration made in accordance with the requirements of Directive 2014/53/EU Of the European Parliament and of the Council of 16 April 2014 on the harmonization of the laws of the Member States relating to the making available on the market of radio equipment. The declaration of conformity is issued under the sole responsibility of the manufacturer.



**Manufacturer's Name:** NIHON KOHDEN CORPORATION  
**Business Address:** 1-31-4 Nishiochiai, Shinjuku-ku  
Tokyo 161-8560, Japan

**European Representative:** NIHON KOHDEN EUROPE GmbH  
**Address:** Raiffeisenstrasse 10, D - 61191 Rosbach, Germany

**Product Name and Model Name:** Wireless LAN Station                      QI-170P

**Notified Body's Name and No.:** UL Japan, Inc., No.1731(Module B)

**EU-Type examination Certificate No.:** ULAR2106094

**Standard Applied:** IEC 60601-1: 2005  
IEC 60601-1 Amendment 1: 2012  
IEC 60601-1-2: 2007  
EN 300 328 V2.2.2  
EN 301 893 V2.1.1  
EN 62311: 2008  
EN 62479: 2010

**Authorized Signatory:**

Tokyo, Japan / 29 June 2021  
Place and date of issue

  
Hiroko Hagiwara  
General Manager  
Clinical Development & Regulatory Affairs Division

## EC/MDD DECLARATION OF CONFORMITY

This is a declaration made in accordance with the requirements of Council Directive 93/42/EEC of 14 June 1993 concerning medical devices (MDD 93/42/EEC).



**Manufacturer's Name:** NIHON KOHDEN CORPORATION  
**Business Address:** 1-31-4 Nishiochiai, Shinjuku-ku  
Tokyo 161-8560, Japan

**European Representative:** NIHON KOHDEN EUROPE GmbH  
**Address:** Raiffeisenstrasse 10, D - 61191 Rosbach, Germany

**Product Name and Model Name:** Wireless LAN Station                      QI-170P  
**Classification:** IIa

Each kind of medical device to which the Full Quality Assurance Procedures (Annex II) have been applied complies with the applicable provisions of the essential requirements, the classification rules, at each stage, from the design of the device until its final inspection before being supplied.

**Notified Body:** BSI Group The Netherlands B.V.  
**EC Certificate:** CE 01342

**Standard Applied:** IEC 60601-1: 2005  
IEC 60601-1 Amendment 1: 2012  
IEC 60601-1-2: 2011  
IEC 60601-1-6: 2010  
IEC 60601-1-6 Amendment 1: 2013  
IEC 60601-1-8: 2006  
IEC 60601-2-27: 2011  
IEC 80601-2-30: 2009  
IEC 80601-2-30 Amendment 1: 2013  
IEC 60601-2-34: 2011  
IEC 60601-2-49: 2011  
ISO 80601-2-55: 2011  
ISO 80601-2-56: 2009  
ISO 80601-2-61: 2011  
IEC 62304: 2006  
IEC 62366: 2007  
IEC 62366 Amendment 1: 2014  
EN ISO 14971: 2012  
EN ISO 13485: 2016  
EN 1041: 2008  
EN 1041 Amendment 1: 2013  
EN ISO 15223-1: 2016

**Authorized Signatory**

Tokyo, Japan / 31 March 2021  
\_\_\_\_\_  
Place and date of issue

  
\_\_\_\_\_  
Hiroko Hagiwara  
General Manager  
Clinical Development & Regulatory Affairs Division

## RoHS DECLARATION OF CONFORMITY

This is a declaration made in accordance with the requirements of Council Directive 2011/65/EU of 8 June 2011 and 2015/863/EU of 31 March 2015 concerning the restriction of the use of certain hazardous substances in electrical and electronic equipment.



**Manufacturer's Name:** NIHON KOHDEN CORPORATION-  
**Business Address:** 1-31-4 Nishiochiai, Shinjuku-ku, Tokyo 161-8560, Japan

We hereby certify that following product(s) conform to the European Union's Restriction on Use of Hazardous Substances in Electrical and Electronic equipment (RoHS) Directive 2015/863/EU for ten regulated substances listed below.

<b>Product Name(s) :</b>	Bedside Monitor	BSM-1733
	Bedside Monitor	BSM-1753
	Bedside Monitor	BSM-1763
	Bedside Monitor	BSM-1773
	Software Kit	QS-065P
	Wireless LAN Station	QI-170P

**List of environmentally hazardous substances:**

- 1) Lead
- 2) Mercury
- 3) Cadmium
- 4) Hexavalent Chromium
- 5) Polybrominated biphenyls (PBB)
- 6) Polybrominated diphenyl ethers (PBDE)
- 7) Bis(2-ethylhexyl) phthalate (DEHP)
- 8) Butyl benzyl phthalate (BBP)
- 9) Dibutyl phthalate (DBP)
- 10) Diisobutyl phthalate (DIBP)

**Harmonised Standards Applied:** EN 50581:2012

**Authorised Signatory:**

Tokyo, Japan/ 31 March 2021  
Place and date of issue



Hiroko Hagiwara  
General Manager  
Clinical Development & Regulatory Affairs Division